Author Response

Authors' Response

Authors: Benjamin J. Oldfield, MD, Rosalyn W. Stewart, MBA, MD, MS

Abstract

To the Editor: We appreciate the clarifications provided in the letter by Dr Muncie. We apologize for the typographical errors in our figure. The current recommendations for immunoprophylaxis against pneumococcal disease are indeed confusing and changing frequently. Four different pneumococcal vaccines have been licensed since 1977 (only the two mentioned in our article remain licensed), and many practitioners have observed multiple adjustments to these recommendations during their careers.1

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Epidemiology and Prevention of Vaccine-Preventable Diseases, 13th ed. Hamborsky J, Kroger A, Wolfe S, eds. Washington, DC: Public Health Foundation; 2015:279-296.
 
2. Kobayashi M, Bennett NM, Gierke R, et al. Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2015;64:944-947.
 
3. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012;61:816-819.